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A fuzzy expert system (FES) for the prediction of prostate cancer (PC) is prescribed in this article.
Age, prostate-specific antigen (PSA), prostate volume (PV) and % Free PSA (%FPSA) are fed as
inputs into the FES and prostate cancer risk (PCR) is obtained as the output. Using knowledge
based rules in Mamdani type inference method the output is calculated. If PCR ≥ 50%, then the
patient shall be advised to go for a biopsy test for confirmation. The efficacy of the designed FES
is tested against a clinical data set. The true prediction for all the patients turns out to be 68.91%
whereas only for positive biopsy cases it rises to 73.77%. This simple yet effective FES can be used
as supportive tool for decision making in medical diagnosis.
I. INTRODUCTION
Artificial intelligence (AI) is defined as the intelligence processed by machines. With the advancement in the
computer system, machines exhibit tasks which normally need human intelligence. Development of AI techniques has
revolutionized many areas like robotics, transportation, education, marketing etc. including medical diagnosis and
health care. Medical diagnosis deals with the analysis of complex medical data. The primary job in medical diagnosis
is to reach to a decision using expert’s logical reasoning. Handling large complex data and many uncertainties make
this job very difficult. AI appears to be very handy for this job. AI in medical diagnosis has added expert human
reasoning in simulation of computer-aided diagnosis process. There are different AI methods used in medical diagnosis,
fuzzy logic is one of the most popular one. AI is the technique of mimicking human intelligence by the help of advance
computer systems. Human brain takes natural languages as inputs which aren’t feasible to be represented by Boolean
logic (either true or false). So, there is a requirement of representation outside these two possibilities. Fuzzy logic
exactly does that. Fuzzy logic appears closer to the way human brain works. Therefore, in AI, fuzzy logic shows the
sign of being a natural choice.
Uncertainties and imprecision are connected with every aspect of our day to day life activities. Specifically in medical
diagnosis domain, one encounters a lot of uncertainty and vagueness. It becomes very difficult to identify a particular
disease from the said symptoms of the patients, as it contains lot of approximate and inaccurate information. On the
other hand, a particular symptom can possibly lead to many different disjoint diseases, whereas for the same disease,
the symptom may manifest itself in completely different ways from person to person. There are inherent uncertainties
in the process of decision making in medical diagnosis, even for an expert too. To tackle these inexact, linguistic
inputs, fuzzy logic based expert system is turned out to be very useful. The concepts of fuzzy set and fuzzy logic were
introduced by Prof. L. A. Zadeh [1]. In contrast to binary logic, fuzzy logic deals with multi-valued logic which is a
mathematical tool to represent the real world effectively. Due to its usefulness and simplicity, fuzzy logic has drawn
huge attention of interdisciplinary researchers round the globe.
Fuzzy logic based expert systems are widely used in many areas of medical diagnosis and decision-making process.
Particularly, in the area of prostate cancer, very few literature are available [2–9]. These literature address the problem
in different angles and also use fuzzy logic in disjoint ways. Some researchers have used hybrid system to treat this
problem. We focus our attention to fuzzy logic based expert system to predict the prostate cancer risk. From careful
study of the literature, we found that %FPSA is a very crucial parameter, along with age, PSA and PV for early
detection of PC. Therefore, we formulate a fuzzy expert system by taking care of all these inputs.
The paper is organized as follows. Section II describes the fuzzy expert system, where all the inputs and the output
are discussed. In section III, we apply our FES to a medical data set and discuss our findings. Finally we summarize
and conclude in section IV.
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2II. FUZZY EXPERT SYSTEM (FES)
An expert system which uses fuzzy logic instead of Boolean logic is called fuzzy expert system (FES). A FES is
a form of artificial intelligence which deals with membership functions and some prescribed rule base to evaluate a
set of data. Fuzziness is introduced to the crisp inputs of a FES by means of suitable membership functions. Once
membership functions are defined for all input variables, then they are fed to a particular inference method for further
action. Here, we have used Mamdani (max-min) inference method which is most popular in literature. Rules of the
FES developed here are of IF-THEN form. Mamdani type inference method results in fuzzy sets as output. For
a given set of input values, some relevant rules will be fired to produce a fuzzy output in Mamdani type inference
method. Fuzzy output is defuzzified using different techniques to obtain crisp output. Centroid method is used for
defuzzification in our FES. General structure of a FES is shown in below figure 1.
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FIG. 1: General architecture of a FES.
We have used medical data of the patients as given in reference [2]. Depending on the data set, the range of different
inputs are determined. In the following two subsections, we discuss about different inputs and the output of the FES.
A. Input variables
1. Age
Age of man is an important parameter to calculate the risk factor for prostate cancer. For a man having no family
history of PC, the chance of getting it increases after the age of 50. This number changes from race to race. However,
two out of three PCs are diagnosed in men at the age of 65 or above. The input variable “age” is represented by four
fuzzy sets, namely, “very young”, “young”, “middle age” and “old”. First and fourth fuzzy sets are represented by
trapezoidal membership functions whereas for second and third we have used triangular membership functions. Table
I lists crisp sets and the corresponding fuzzy sets for the input “age”. The membership functions for the same are
plotted in figure 2.
3TABLE I: Fuzzification of the input variable “age”.
Input variable Crisp set Fuzzy set
Age (year) 0-30 Very young
20-50 Young
30-60 Middle age
40-100 Old
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FIG. 2: Membership functions for “age”.
2. Prostate-specific Antigen (PSA)
PSA has altered drastically the management of prostate cancer in men. The PSA test for blood can provide early
stage detection of PC [10]. PSA is a protein secreted by the prostate gland which helps to keep the semen in liquid
form. Some parts of this protein will pass into blood which give rise to the increase in normal PSA level. Elevation
in PSA level in blood depends up on the health of prostate gland and the age of the person. A healthy prostate
will release less PSA in blood compared to a cancerous gland. So, a rise in PSA level over normal range could be
a possible indicator of PC. Although, elevated PSA level may be caused due to other factors like acute bacterial
prostatitis, enlargement of prostate and other urinary retention. The measurement of PSA is expressed as nanograms
per milliliter of blood. The normal range of PSA number can be age specific and also race specific. The input variable
“PSA” is represented by five fuzzy sets, e.g., “very low”, “low”, “middle”, “high” and “very high”. For the first and
fifth sets we have used trapezoidal membership functions while for the rest, triangular membership functions are used.
In table II, we have shown the crisp sets and the corresponding fuzzy sets. The plot of the membership functions for
the input “PSA” is displayed in figure 3.
4TABLE II: Fuzzification of the input variable “PSA”.
Input variable Crisp set Fuzzy set
PSA (ng/ml) 0-4 Very low
2-8 Low
4-12 Middle
8-16 High
12-50 Very high
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FIG. 3: Membership functions for “PSA”.
3. Prostate Volume (PV)
A healthy human male’s prostate is marginally larger than a walnut. It is a crucial parameter for early detection of
PC. There is a characteristic pattern in the growth of prostate with age. That pattern can change from race to race.
With the increase in the prostate volume there is a possibility of sampling error in systematic sextant needle biopsy.
It is wise to use prostate volume as a factor while determining the necessity to repeat biopsy with initial negative
result [11]. Prostate is mainly divided in four zones in pathological terminology and total prostate volume as well
as transition zone volume are measured in ultrasound. According to transrectal ultrasound (TRUS) guidance [12],
prostate width (W ) (maximal transverse diameter) is estimated on an axial image. Prostate length (L) (longitudinal
diameter, the distance between proximal external sphincter and urinary bladder) and height (H) (maximal antero-
posterior diameter) are measured on a mid-sagittal image [13]. The total prostate volume (TPV) is calculated using
the prolate elliptical formula, TPV = pi
6
×W ×L×H . The transition zone volume can be calculated using the same
formula by measuring the required dimensions from the ultrasound. The length, width and height changes with the
age. The rate of change for the length is significant compared to other two dimensions as the man approaches the
5age 60. So, based on the above information we have divided the input “prostate volume” in four fuzzy sets such
as “small”, “middle”, “big” and “very big”. Trapezoidal and triangular membership functions are used to represent
them. Crisp sets, fuzzy sets and the membership functions are listed in table III and figure 4 respectively for the
input variable “prostate volume”.
TABLE III: Fuzzification of the input variable “PV”.
Input variable Crisp set Fuzzy set
PV (ml) 0-60 Small
30-120 Middle
60-200 Big
180-300 Very big
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FIG. 4: Membership functions for “PV”.
4. Percentage of Free PSA (%FPSA)
PSA is a protein which exists in different forms in serum. PSA circulates through body via bound to some
other proteins or in unbound form. Free PSA test measure the ratio of the unbound PSA to bound PSA whereas
normal PSA test measure the total PSA (both bound and unbound) level in blood [14, 15]. %FPSA is calculated as
Free PSA
TotalPSA
× 100%. As we already discussed that PSA level may rise not only due to cancerous prostate but because of
many other reasons. Therefore, for the early detection of the PC, which is potentially in its curable stage, requires a
lower cutoff for PSA level, gives rise to avoidable biopsies. It is also observed that the men with PC are likely to have
%FPSA lower than those of benign disease [14, 16]. So, along with an elevated PSA level, %FPSA cutoff will be a
6good indicator for the early stage detection. Based on this we have categorized the input variable “%FPSA” in three
fuzzy sets, namely, “low”, “middle” and “high”. For their representation we have used trapezoidal and triangular
membership functions. Crisp sets, fuzzy sets and the membership functions are shown in table IV and figure 5.
TABLE IV: Fuzzification of the input variable “%FPSA”.
Input variable Crisp set Fuzzy set
%FPSA 0-11 Low
9-21 Middle
18-100 High
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FIG. 5: Membership functions for “%FPSA”.
B. Output Variable
1. Prostate Cancer Risk (PCR)
The output of the FES is PCR. Numerical value of it will help us to identify the benignant one or the malignant one
by considering PSA, age, PV and %FPSA of the patient as input variables for the FES. If the PCR % value is ≥ 50,
then we can anticipate that the patient has a high chance of having PC. Therefore, he will be recommended for biopsy
test for confirmation. The positive biopsy result confirms our prediction whereas negative result contradicts. The case
of PCR % value < 50 can be understood in similar fashion. The output variable, PCR is categorized into three fuzzy
sets, namely, “low”, “middle” and “high”. Trapezoidal and triangular membership functions are used to represent
them. The table V and the figure 6 are displaying these fuzzy sets and their membership functions respectively.
7TABLE V: Fuzzification of the output variable PCR.
Output variable Crisp set Fuzzy set
Prostate Cancer Risk (%) 0-30 Low
10-50 Middle
45-100 High
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FIG. 6: Membership functions for “PCR”.
C. Fuzzy Rule Base
In this FES, four input variables are age, PSA, PV and %FPSA which are represented by four, five, four and three
membership functions respectively. So, our FES has total 4 × 5 × 4× 3 = 240 rules to estimate PCR as the output,
which is also characterized by three membership functions. Some of the selected rules are displayed below.
1. If (Age is vy) and (PSA is vl) and (PV is small) and (%FPSA is low) then (PCR is low) (1)
8. If (Age is vy) and (PSA is vl) and (PV is big) and (%FPSA is mid) then (PCR is low) (1)
65. If (Age is yo) and (PSA is vl) and (PV is middle) and (%FPSA is mid) then (PCR is low) (1)
97. If (Age is yo) and (PSA is hi) and (PV is small) and (%FPSA is low) then (PCR is high) (1)
130. If (Age is ma) and (PSA is vl) and (PV is verybig) and (%FPSA is low) then (PCR is low) (1)
172. If (Age is ma) and (PSA is vh) and (PV is middle) and (%FPSA is low) then (PCR is high) (1)
196. If (Age is ol) and (PSA is lo) and (PV is middle) and (%FPSA is low) then (PCR is low) (1)
240. If (Age is ol) and (PSA is vh) and (PV is verybig) and (%FPSA is high) then (PCR is mid) (1)
For example, rule 1 can be elucidated as, if age of the patient is very young, PSA is very low, PV is small and %FPSA
is low then PCR for that patient is low. The wieght of this rule is maximum which is specified by number 1 in the
parentheses after the rule. Other rules can be spelled out in similar manner. Surface plot gives a visualization of the
rules applied in FES. Since, our FES has four inputs and one output, it is not possible to plot the dependence of the
8output against all inputs. So, in surface plot we have plotted the output against any two input variables by keeping
some reference values for the rest two inputs. Fig 7 displays two such surface plots where relevant parameters are
mentioned in the caption. For example, PCR is high (very high) for %FPSA value less than 20% (10%) irrespective
of the patient’s age.
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FIG. 7: Surface plot of four-input FES (left) by taking two variables as inputs and PCR as output while keeping reference
values for other two inputs. For the figure on the left, age & %FPSA are inputs and reference values for PV & PSA are 100 and
6 respectively. The figure on the right, we have taken PSA & age as inputs while fixing reference values for PV and %FPSA
at 100 and 15 respectively.
9D. Defuzzification & Mamdani Inference Engine
Defuzzification is the process of obtaining a precise quantity from a fuzzy set. In this FES, we have employed
centroid method to defuzzify which is given by
z¯ =
∫
µC(z) · z dz∫
µC(z) dz
. (1)
For a given set of input variables, viz. age=56, PSA=9.05, PV=39 and %FPSA=8.51, we calculate the corresponding
degrees of membership by identifying the proper fuzzy sets for each input variable. This particular choice of inputs
will fire, say k number of rules. Truth degree (αi) of the i
th firing rule is determined by taking min of corresponding
membership values of each input variable. Thereafter, max of all αi will be the membership value of PCR. This is
how Mamdani max-min inference technique is used. Then applying the centroid method, we obtain crisp value of
PCR. Steps are shown below for the above mentioned input data.
1. Age = 56, µma(56) = 0.2 and µol(56) = 0.533.
2. PSA = 9.05, µmi(9.05) = 0.7375 and µhi(9.05) = 0.2625.
3. PV = 39, µsl(39) = 0.7 and µmi(39) = 0.3.
4. %FPSA = 8.51, µlo(8.51) = 0.83.
For the above set of input data, eight rules will come into action and yield
1. α145 = min(0.2, 0.7375, 0.7, 0.83) = 0.2,
2. α148 = min(0.2, 0.7375, 0.3, 0.83) = 0.2,
3. α157 = min(0.2, 0.2625, 0.7, 0.83) = 0.2,
4. α160 = min(0.2, 0.2625, 0.3, 0.83) = 0.2,
5. α205 = min(0.533, 0.7375, 0.7, 0.83) = 0.533,
6. α208 = min(0.533, 0.7375, 0.3, 0.83) = 0.3,
7. α217 = min(0.533, 0.2625, 0.7, 0.83) = 0.2625,
8. α220 = min(0.533, 0.2625, 0.3, 0.83) = 0.2625,
which further provides
α = max(α145, α148, α157, α160, α205, α208, α217, α220),
= max(0.2, 0.2, 0.2, 0.2, 0.533, 0.3, 0.2625, 0.2625) = 0.533.
Using α = 0.533, and applying centroid method we get the PCR is 74.01%, which is much greater than our cutoff
value of 50%. Therefore, in this case, the patient should be advised to go for a biopsy to confirm. We have used fuzzy
logic toolbox of Matlab software for calculation of the entire set of medical data of 119 patients. Block diagram of
FES is portrayed in the figure 8.
III. RESULTS AND DISCUSSION
We have applied our proposed FES to analyze the data (given in reference [2]) presented in table VI. Here, the
range of different inputs are chosen depending upon the minimum and the maximum values of the respective input
variables. For example, for the input “PV”, the maximum value is 235 ml and the minimum value is 15 ml. Therefore,
we have chosen the range for “PV” to be 0 − 300 ml. Feeding the four inputs into the FES, we obtain PCR as the
output. If the value of PCR is greater or equal to 50%, then the patient should be advised to go for a biopsy test
to confirm whether the prostate problem is of benignant or malignant type. We have compared outcomes of our
FES with the results of biopsy. Out of total 119 patients, 61 patients had positive biopsy results, while the rest 58
patients had negative results. The true prediction by our FES is 68.91%. The proposed FES has correctly predicted
the positive biopsy results for 45 patients (73.77%) and the negative biopsy results for 37 patients (63.79%). True
prediction percentage of our FES is better than that of the existing systems for prediction in literature. Saritas et.
al [2] has claimed 64.71% true prediction for the same set of data, while online calculator for PC prediction and
FPSA/PSA ratio provide only 62.18% and 60.50% respectively. Inclusion of one parameter has definitely increased
the number of rules, but the prediction of the designed FES has become more accurate.
10
System proscanc: 4 inputs, 1 output, 240 rules
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FIG. 8: FES structure
IV. SUMMARY AND CONCLUSIONS
We have developed a fuzzy rule based expert system to predict the chances of having prostate cancer (PC) from a
given set of input parameters. For this FES, we used age, PSA, PV and %FPSA as the inputs to calculate prostate
cancer risk (PCR) as the output. Existing literature on FES for PC, has mainly dealt with first three of the above
mentioned inputs. The cutoff of %FPSA is also a very crucial parameter along the PSA value, as it can reduce
avoidable biopsy tests significantly. Most important advantages, apart from the cost of biopsy, the patient who do
not need biopsy will be free from uneasiness and worries of the procedure, as well as the possible aftermath medical
complications [14]. Therefore, inclusion of this parameter in our FES was essential and it has altered the outcome
appreciably. For a case study of 119 patients, our FES has correctly predicted for 82 patients (68.91%). It is to be
noted that, true prediction percentage for positive biopsy cases is excellent (73.77%) whereas for the negative biopsy
cases, it deviates slightly. The salient feature of our FES is that, the true prediction for positive biopsy is much higher
compared to negative biopsy cases. This may cause an unnecessary biopsy test (along the with the pain associated
with it) but it will certainly save a life. One should keep in mind that the FES designed here is not to confirm whether
a person is having PC or not, but to assist a doctor to take a decision whether to go for biopsy or not. Since, four
inputs are considered for this FES, number of rules has increased which makes it little complicated to start with. Once
11
the burden of deciding these rules based on experts’ opinion are done, it does the prediction efficaciously. On the other
hand, the behaviour of different bio-markers varies drastically from race to race, from demographic region to region,
family history, life style, food habits and also depends on many more hidden variables. So, modification in cutoff
values has to be done accordingly to use the FES. Hybridizing our FES with other AI techniques and incorporating
more experts’ opinions may lead to an improved result.
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TABLE VI: Data set containing the information of age, PSA, PV and
%FPSA values and biopsy results for 119 patients given in the reference
[2]. PCR values are calculated by our FES using Matlab fuzzy logic
toolbox.
Age PSA PV
%FPSA
Biopsy
PCR (%)
Age PSA PV
%FPSA
Biopsy
PCR (%)(year) (ng/ml) (ml) result (year) (ng/ml) (ml) result
44 7.6 38 10.53 Negative 45.42 67 15.93 69 6.09 Positive 74.82
51 6.76 15 4.14 Positive 57.78 67 28 47 15.00 Positive 74.15
51 44 83 31.82 Positive 30.00 68 5.09 47 2.36 Negative 42.96
53 4.5 39 18.89 Negative 19.96 68 5.51 45 11.25 Negative 21.28
53 5.83 25 6.86 Negative 53.32 68 7.2 33 3.61 Positive 67.21
53 8.34 25 7.43 Negative 73.83 68 9.25 91 3.57 Positive 74.03
54 5.62 28 14.95 Negative 21.96 68 12.1 61 16.12 Negative 74.25
54 17.3 90 27.46 Negative 30.00 68 23.7 109 10.04 Positive 73.55
54 17.3 45 8.90 Positive 73.91 68 140 117 14.29 Positive 74.80
55 10.51 54 22.45 Negative 23.57 68 140 54 3.29 Positive 74.70
56 8.9 26 34.16 Negative 18.80 69 8.8 34 8.98 Positive 74.40
56 9.05 39 8.51 Positive 74.07 69 11.06 38 29.84 Negative 26.64
56 16 146 8.44 Negative 74.07 69 15.31 74 30.57 Positive 30.00
57 12.56 52 65.84 Negative 30.00 69 61 46 9.93 Negative 73.65
58 4.48 67.5 16.07 Negative 16.09 69 70.56 45 6.02 Positive 73.98
58 4.62 48 11.04 Negative 17.62 69 146 29 7.33 Positive 75.10
58 5.2 58 23.46 Negative 12.80 70 5.39 120 19.11 Negative 23.58
58 16.39 27 92.07 Negative 30.00 70 5.39 42 12.80 Negative 19.91
59 0.28 168 42.86 Negative 13.30 70 13 40 15.46 Negative 74.39
59 8.36 55 7.54 Positive 74.31 70 13.95 119 13.76 Negative 74.02
59 18.2 77 17.75 Negative 73.76 70 19.2 44 10.10 Positive 73.49
59 19.48 79 25.00 Positive 30.00 70 21.94 29 7.11 Positive 75.17
59 22.51 42 7.02 Negative 74.22 70 27.7 63 8.99 Negative 74.40
59 22.65 66 10.82 Negative 73.88 71 6.08 48 21.38 Positive 13.52
60 6.58 65 14.74 Negative 24.82 71 12.64 50 7.99 Positive 74.39
60 10.6 30 16.79 Positive 61.27 71 22 57 12.00 Positive 74.59
60 11.45 46 19.48 Negative 53.47 72 6.64 32 27.41 Negative 12.43
60 14.79 38 6.90 Positive 74.39 72 13.31 33 3.83 Positive 74.40
60 15.51 35 21.02 Negative 30.00 72 13.31 33 3.76 Positive 74.40
61 4.6 37 10.87 Negative 25.02 72 20 48 7.90 Positive 74.22
61 10.33 62 25.36 Negative 23.78 72 46 36 10.70 Positive 73.81
61 10.36 35 19.79 Negative 47.88 72 77 48 8.31 Positive 74.22
61 10.59 56 17.00 Positive 60.72 73 4.65 41 41.94 Negative 12.52
61 18.3 62 6.99 Positive 74.46 73 7.25 19 5.52 Negative 67.73
62 6.12 52 24.18 Negative 12.86 73 7.6 74 31.32 Positive 12.09
62 6.2 25 4.35 Positive 56.05 73 19 90 6.84 Positive 73.98
62 8.37 43 11.23 Negative 40.23 73 29.52 91 9.82 Negative 73.73
62 8.79 45 10.92 Positive 48.39 73 47.4 87 15.89 Positive 74.11
62 20 53 5.20 Positive 74.55 74 12.52 27 11.82 Negative 74.47
62 51.74 29 6.80 Positive 74.55 74 150 54 16.67 Positive 74.09
63 8.8 31 22.50 Positive 19.22 75 4.61 16 17.57 Positive 18.39
64 5.7 36 29.82 Negative 12.71 75 10 34 7.60 Positive 73.98
64 6.96 45 9.20 Negative 60.28 76 9.81 56 37.41 Negative 21.46
64 8 40 7.50 Positive 74.39 76 13.61 61 19.91 Positive 52.54
64 11.08 26 10.11 Negative 59.05 76 13.83 54 19.96 Positive 51.76
64 16.28 21 6.94 Positive 74.70 76 21 86 5.43 Positive 74.15
65 4.39 30 21.64 Negative 13.42 77 10 60 6.00 Positive 73.98
65 5.15 47 15.73 Negative 19.46 77 12.05 28 27.05 Positive 30.00
65 7.61 23 5.78 Positive 70.95 77 56 51 7.34 Positive 74.46
65 7.82 75 22.76 Negative 13.04 78 4.5 180 20.44 Negative 18.05
65 8.33 32 14.53 Positive 38.08 78 26.1 46 8.62 Negative 74.07
66 4.38 33 23.52 Negative 12.78 78 26.13 235 8.27 Negative 74.96
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TABLE VI – continued from previous page
Age PSA PV
%FPSA
Biopsy
PCR (%)
Age PSA PV
%FPSA
Biopsy
PCR (%)(year) (ng/ml) (ml) result (year) (ng/ml) (ml) result
66 6.72 61 13.84 Positive 25.38 78 31.6 57 8.86 Negative 74.50
66 7.65 89 23.66 Negative 12.90 79 17.1 41 7.60 Negative 74.31
66 9 74 18.89 Positive 53.84 80 69.51 28 28.77 Positive 30.00
66 9.86 49 23.83 Negative 21.69 81 4.5 28 21.56 Positive 13.45
67 4.39 28 0.91 Negative 23.99 81 68.36 52 35.27 Positive 30.00
67 5.65 24 10.27 Positive 46.65 88 10.4 32 7.50 Positive 74.22
67 6.24 65 21.96 Negative 13.31
67 8.2 36 20.37 Positive 31.78
67 9.68 41 7.44 Positive 74.18
